
Alicia Morgans, MD, MPH
@capsurvivorship
Physician, researcher, mom; passionate about improving the lives of men and women with cancer. Views are my own. tinyurl.com/2p83fzb7
ID: 806171707274891264
06-12-2016 16:21:27
338 Tweet
1,1K Followers
233 Following


We are presenting today in the poster session, and happy to see that Black men did at least as well in disease response and control outcomes as White men with enzalutamide. #GU22 Similar findings to studies with other agents by Dan George Elisabeth Heath

Mind bending approaches that give us a glimpse of where we're going in predicting benefit from treatment in prostate cancer. Hoping to avoid unnecessary treatment if it is the right thing to do someday. View it virtually if you missed in person! #GU22 Daniel E Spratt @awesama_md!

Thank you for mentioning the work, Toni Choueiri, MD . Hoping to bridge gaps and reach equality in outcomes, one step at a time. Stephen Freedland, MD #GU22 Dana-Farber Lank Center for Genitourinary Oncology

Matthew Smith expertly presents the long awaited ARASENS study of mHSPC pts receiving ADT+doce+/- darolutamide. Overall survival HR 0.68 with darolutamide. Triplet wins again. Check it out online if not in person! #GU22 Great moderating by David VanderWeele MD PhD

What an oral abstract session #GU22 . A year away, and we come back even stronger. MAGNITUDE, PROpel, ARASENS and PRESIDE - 4 studies demonstrating the continued power of targeting the AR. Neeraj Agarwal, MD, FASCO Oliver Sartor @morr316 UroToday.com Felix Feng


>15,000 pts completed the WHOLE survey in 60 days! They want their voices to be heard. Grateful to the pts and team for allowing me to participate in this phenomenal effort, and to have a chance to amplify the patient voice. #GU22 UroToday.com Dana-Farber Lank Center for Genitourinary Oncology Toni Choueiri, MD

Looking forward to a great program! So glad to have a superstar set of colleagues to work with on this Petros Grivas Atish Choudhury, MD PhD Bradley McGregor Guru P. Sonpavde, MD Tanya Dorff Neha Vapiwala and so many others!

Could not agree more! There is so much content to absorb, and CME, too. Love the focus on multidisciplinary collaboration and patient engagement! Larissa Nekhlyudov Ann Partridge MD, MPH Dana-Farberās Breast Oncology Center Dana-Farber Lank Center for Genitourinary Oncology Dana-Farber's Young-Onset Colorectal Cancer Center Dana-Farber Dana-FarberYAProgram

So excited for this talk by @ohamnvik . Understanding unique challenges in cancer screening and follow up is critical to ensuring the best care for all patients. Ann Partridge MD, MPH Larissa Nekhlyudov Dana-Farber

Great networking conversation learning about ā¦Atish Choudhury, MD PhDā© ās path to success. #GDUGU2022


Always a pleasure to talk with Axel S. Merseburger , especially to review such monumental efforts by the team working on #PRESIDE . Thank you for sharing your findings with UroToday.com !

So well deserved! Congratulations Elizabeth Plimack MD . I canāt wait to see how your vision shapes the Cancer Center and positivity affects things for patients and their loved ones.

Looking forward to an inspiring and data packed meeting! If you canāt be there in person, catch the virtual meeting #ASCO22 and coverage UroToday.com PCF Science Charles Ryan Neeraj Agarwal, MD, FASCO Toni Choueiri, MD Axel S. Merseburger David VanderWeele MD PhD Tanya Dorff !

Wonderful talks by all, including Prof. Ursula Vogl ! It was the perfect group to engage with in this final EAU session before the race to the airport:)

Retweeting this invitation for fellows and late stage clinical trainees looking to establish an academic career and join the #ThoughtLeadersoftheFuture program Prostate Cancer Foundation William K. Oh MD Howard Soule UroToday.com Zach Klaassen @morr316 Neeraj Agarwal, MD, FASCO Phil Kantoff Neha Vapiwala


OncoDaily Dana-Farber Thanks to co-directors Larissa Nekhlyudov & Alicia Morgans, MD, MPH! Learn about the latest, evidence-based tools to care for cancer survivors: cmecatalog.hms.harvard.edu/cancer-survivoā¦

